A Phase I Dose-Escalation and Pharmacokinetic Study of TrasGEX in Patients With Locally Advanced or Metastatic HER-2-positive Cancer

Trial Profile

A Phase I Dose-Escalation and Pharmacokinetic Study of TrasGEX in Patients With Locally Advanced or Metastatic HER-2-positive Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Glycotope
  • Most Recent Events

    • 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2013 Planned End Date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 08 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top